Gaspar Carreño M, Romero Crespo I, Querol Masia M, Navarro Garcia J, Tudela Ortells V, Moreno Royo L
Farmacéutica Especialista en Farmacia Hospitalaria, Servicio de Farmacia, Centro de Recuperación y Rehabilitación de Levante, Valencia, España.
Farm Hosp. 2012 Jan-Feb;36(1):16-23. doi: 10.1016/j.farma.2010.11.003. Epub 2011 May 17.
To evaluate the results for implementing a pharmaceutical care programme aimed at optimising personalised pharmacotherapeutic treatment in a Trauma Centre with electronic medical records (EMR) and an integral system for personalised medication dispensing (ISPMD).
A three-year observational, retrospective study (2007-2009). On a daily basis, we checked the pharmaceutical treatment of patients admitted to hospital units with ISPMD. The medication-related problems (MRP) and medication errors (ME) were identified and classified by recording them on a standardised document. We also recorded data on the Pharmaceutical Interventions performed in accordance with fitness and level of acceptance. We used the laser method to identify patients with pharmacotherapy improvement opportunities (MRP and/or ME).
One thousand nine-hundred and seventy-one pharmaceutical interventions (PI) were found after having reviewed 124 336 treatment lines, resulting in 12 PI for every 100 patients. The prevalence of patients with MRP was 12%, distributed as such: 50.66% were safety-related, 22.98% indication-related, 12.23% effectiveness-related and 14.13% adherence-related. The main drug groups involved were: anti-infectious agents (29%), drugs for the musculoskeletal system (21%), drugs for blood and haematopoietic organs (12%), and drugs for the nervous system (11%). The active ingredient that required most PI in 2007 was dexketoprofen (15.6%), followed by ketorolac (12.4%). In 2008, it was dexketoprofen (22.0%) followed by gentamicin (7.3%), and in 2009 enoxaparin (19.0%) followed by dexketoprofen (14.3%). The origin of MRP was due to ME in 91% of cases in 2007 and 81% in 2008, decreasing to 53% in 2009. PI fitness, as percentages (CI 95%) were considered: Important PI [30.29 (10.19-49.95)]; Very important PI [38.36 (35.45-73)]; Acceptable PI [82.10 (52.28-111.10)].
Optimising personalised pharmacotherapeutic treatment by implementing an interdisciplinary Pharmaceutical Care programme promotes team work, and as a result improves rational and safe medication dispensing.
评估在一家拥有电子病历(EMR)和个性化药物调配综合系统(ISPMD)的创伤中心实施旨在优化个性化药物治疗方案的药学服务项目的效果。
一项为期三年的观察性回顾性研究(2007 - 2009年)。我们每天检查通过ISPMD入住医院各科室患者的药物治疗情况。通过在标准化文件上记录来识别和分类药物相关问题(MRP)及用药差错(ME)。我们还记录了根据适用性和接受程度实施的药学干预的数据。我们使用激光方法识别有药物治疗改进机会(MRP和/或ME)的患者。
在审查了124336条治疗记录后发现1971次药学干预(PI),即每100名患者有12次PI。MRP患者的患病率为12%,分布如下:与安全性相关的占50.66%,与适应证相关的占22.98%,与有效性相关的占12.23%,与依从性相关的占14.13%。主要涉及的药物类别有:抗感染药(29%)、肌肉骨骼系统用药(21%)、血液和造血器官用药(12%)以及神经系统用药(11%)。2007年需要最多PI的活性成分是右酮洛芬(15.6%),其次是酮咯酸(12.4%)。2008年,是右酮洛芬(22.0%),其次是庆大霉素(7.3%),2009年是依诺肝素(19.0%),其次是右酮洛芬(14.3%)。MRP的起因在2007年91%的病例中是ME,2008年为81%,到2009年降至53%。PI的适用性,以百分比(95%置信区间)计为:重要PI [30.29(10.19 - 49.95)];非常重要PI [38.36(35.45 - 73)];可接受PI [82.10(52.28 - 111.10)]。
通过实施跨学科的药学服务项目优化个性化药物治疗可促进团队协作,从而改善合理、安全的药物调配。